Down-Regulation of the Aberrant Expression of the Inflammation Mediator High Mobility Group Box Chromosomal Protein 1 in Muscle Tissue of Patients with Polymyositis and Dermatomyositis Treated with Corticosteroids

Arthritis and Rheumatism

Volumn 50, Issue 5, 2004, Pages 1586-1594

  Ulfgren, Ann Kristin ^a,b   Grundtman, Cecilia ^a   Borg, Kristian ^a   Alexanderson, Helene ^a   Andersson, Ulf ^a   Erlandsson Harris, Helena ^a   Lundberg, Ingrid E ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CHROMOSOME PROTEIN; CORTICOSTEROID; HIGH MOBILITY GROUP B1 PROTEIN; METHOTREXATE; PREDNISOLONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DERMATOMYOSITIS; DRUG MEGADOSE; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; MALE; MICROSCOPY; MONONUCLEAR CELL; MUSCLE BIOPSY; MUSCLE TISSUE; POLYMYOSITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD31; BIOPSY; DERMATOMYOSITIS; DOWN-REGULATION; ENDOTHELIAL CELLS; FEMALE; GLUCOCORTICOIDS; HMGB1 PROTEIN; HUMANS; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; MUSCLE FIBERS; MUSCLE, SKELETAL; PREDNISOLONE; RECOVERY OF FUNCTION;

EID: 2342661145     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.20220     Document Type: Article

References (33)

1. Calogero S, Grassi F, Aguzzi A, Voigtlander T, Ferrier P, Ferrari S, et al. The lack of chromosomal protein Hmg1 does not disrupt cell growth but causes lethal hypoglycaemia in newborn mice. Nat Genet 1999;22:276-80.
2. Bustin M. Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins. Mol Cell Biol 1999;19:5237-46.
3. Gardella S, Andrei C, Ferrera D, Lotti LV, Torrisi MR, Bianchi ME, et al. The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep 2002;3:995-1001.
4. Andersson U, Wang H, Palmblad K, Aveberger AC, Bloom O, Erlandsson-Harris H, et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 2000;192:565-70.
5. Wang H, Yang H, Czura CJ, Sama AE, Tracey KJ. HMGB1 as a late mediator of lethal systemic inflammation. Am J Respir Crit Care Med 2001;164:1768-73.
6. Abraham E, Arcaroli J, Carmody A, Wang H, Tracey KJ. HMG-1 as a mediator of acute lung inflammation. J Immunol 2000;165:2950-4.
7. Kokkola R, Sundberg E, Ulfgren AK, Palmblad K, Li J, Wang H, et al. High mobility group box chromosomal protein 1: a novel proinflammatory mediator in synovitis. Arthritis Rheum 2002;46:2598-603.
8. Hori O, Brett J, Slattery T, Cao R, Zhang J, Chen JX, et al. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin: mediation of neurite outgrowth and co-expression of RAGE and amphoterin in the developing nervous system. J Biol Chem 1995;270:25752-61.
9. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002;418:191-5.
10. Bustin M. At the crossroads of necrosis and apoptosis: signaling to multiple cellular targets by HMGB1. Sci STKE [serial online]. 2002;151:PE39. URL: http://stke.sciencemag.org.
11. Mantegazza R, Bernasconi P, Confalonieri P, Cornelio F. Inflammatory myopathies and systemic disorders: a review of immunopathogenetic mechanisms and clinical features. J Neurol 1997;244:277-87.
12. Dalakas MC. Immunopathogenesis of inflammatory myopathies. Ann Neurol 1995;37 Suppl 1:S74-86.
13. Lundberg I, Brengman JM, Engel AG. Analysis of cytokine expression in muscle in inflammatory myopathies, Duchenne dystrophy, and non-weak controls. J Neuroimmunol 1995;63:9-16.
14. Lundberg I, Ulfgren AK, Nyberg P, Andersson U, Klareskog L. Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Rheum 1997;40:865-74.
15. Authier FJ, Mhiri C, Chazaud B, Christov C, Cherin P, Barlovatz-Meimon G, et al. Interleukin-1 expression in inflammatory myopathies: evidence of marked immunoreactivity in sarcoid granulomas and muscle fibres showing ischaemic and regenerative changes. Neuropathol Appl Neurobiol 1997;23:132-40.
16. Lepidi H, Frances V, Figarella-Branger D, Bartoli C, Machado-Baeta A, Pellissier JF. Local expression of cytokines in idiopathic inflammatory myopathies. Neuropathol Appl Neurobiol 1998;24:73-9.
17. Lundberg I, Kratz AK, Alexanderson H, Patarroyo M. Decreased expression of interleukin-1α, interleukin-1β, and cell adhesion molecules in muscle tissue following corticosteroid treatment in patients with polymyositis and dermatomyositis. Arthritis Rheum 2000;43:336-48.
18. Nyberg P, Wikman AL, Nennesmo I, Lundberg I. Increased expression of interleukin 1α and MHC class I in muscle tissue of patients with chronic, inactive polymyositis and dermatomyositis. J Rheumatol 2000;27:940-8.
19. Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med 1975;292:344-7.
20. Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med 1975;292:403-7.
21. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
22. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
23. Josefson A, Romanus E, Carlsson J. A functional index in myositis. J Rheumatol 1996;23:1380-4.
24. Alexanderson H, Stenstrom CH, Jenner G, Lundberg I. The safety of a resistive home exercise program in patients with recent onset active polymyositis or dermatomyositis. Scand J Rheumatol 2000; 29:295-301.
25. Henriksson KG. "Semi-open" muscle biopsy technique: a simple outpatient procedure. Acta Neurol Scand 1979;59:317-23.
26. Dorph C, Nennesmo I, Lundberg IE. Percutaneous conchotome muscle biopsy: a useful diagnostic and assessment tool. J Rheumatol 2001;28:1591-9.
27. Kokkola R, Li J, Sundberg E, Aveberger AC, Palmblad K, Yang H, et al. Successful treatment of collagen-induced arthritis in mice and rats by targeting extracellular high mobility group box chromosomal protein 1 activity. Arthritis Rheum 2003;48:2052-8.
28. Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC, et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 1992;267:14998-5004.
29. Brett J, Schmidt AM, Yan SD, Zou YS, Weidman E, Pinsky D, et al. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol 1993;143:1699-712.
30. Huttunen HJ, Fages C, Rauvala H. Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-κB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J Biol Chem 1999; 274:19919-24.
31. Degryse B, Bonaldi T, Scaffidi P, Muller S, Resnati M, Sanvito F, et al. The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells. J Cell Biol 2001;152:1197-206.
32. Goodwin GH, Sanders C, Johns EW. A new group of chromatin-associated proteins with a high content of acidic and basic amino acids. Eur J Biochem 1973;38:14-9.
33. Barnes PJ. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci (Lond) 1998;94:557-72.